Docosanol

Docosanol

SCHEMBL4958624

CCCCCCCCCCCCCCCCCCCCCCO.CCO

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

gBgCgDgEgGgHgIgJgKgLgMgN

The experimentally established mechanism targets of Docosanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.93
TSHR P16473 4/20 0.93
LMNA P02545 3/20 0.93
MEN1 O00255 2/20 0.93
KMT2A Q03164 2/20 0.93
HSD17B10 Q99714 1/20 0.93
SMN1; SMN2 Q16637 1/20 0.86
THRB P10828 2/20 0.57
DNM1 Q05193 2/20 0.48
HTT P42858 1/20 0.48
MAPT P10636 1/20 0.48
CES2 O00748 3/20 0.43
CES1 P23141 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cetostearyl Alcohol SCHEMBL1643143 1.00 ALDH1A1 (0.93) ALDH1A1TSHRLMNAMEN1KMT2A
Myristyl Alcohol SCHEMBL2046092 1.00 ALDH1A1 (0.93) ALDH1A1TSHRLMNAMEN1KMT2A
Cetyl Alcohol SCHEMBL1101785 1.00 ALDH1A1 (0.93) ALDH1A1TSHRLMNAMEN1KMT2A
Triacontanol SCHEMBL5609342 1.00 ALDH1A1 (0.93) ALDH1A1TSHRLMNAMEN1KMT2A
Decanol SCHEMBL10594393 1.00 ALDH1A1 (0.93) ALDH1A1TSHRLMNAMEN1KMT2A
Nonanol SCHEMBL2761019 1.00 ALDH1A1 (0.93) ALDH1A1TSHRLMNAMEN1KMT2A
Alcohol SCHEMBL5138742 1.00 ALDH1A1 (0.93) ALDH1A1TSHRLMNAMEN1KMT2A
Cetyl Alcohol SCHEMBL873050 1.00 ALDH1A1 (0.93) ALDH1A1TSHRLMNAMEN1KMT2A
Undecanol SCHEMBL4656406 1.00 ALDH1A1 (0.93) ALDH1A1TSHRLMNAMEN1KMT2A
Alcohol SCHEMBL872545 1.00 ALDH1A1 (0.93) ALDH1A1TSHRLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117777759-A Modified optically variable dye and preparation method thereof 湖南肆玖科技有限公司 2024-03-29 CN claimed
EP-3638251-B1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF LAKEWOOD AMEDEX INC (US) 2024-03-06 EP claimed
EP-4241769-A2 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF Lakewood Amedex, Inc. (US) 2023-09-13 EP claimed
US-20230125677-A1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF LAKEWOOD AMEDEX INC (US) 2023-04-27 US claimed
US-20210361689-A1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF Lakewood Amedex, Inc. 2021-11-25 US claimed
US-20200360415-A1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF Lakewood Amedex, Inc. 2020-11-19 US claimed
EP-3638251-A1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF Lakewood Amedex, Inc. (US) 2020-04-22 EP claimed
WO-2018231863-A1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF LAKEWOOD AMEDEX, INC (US) 2018-12-20 WO claimed
US-20180353529-A1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF Lakewood Amedex, Inc. 2018-12-13 US claimed
CN-108530639-A Efficient water-coal-slurry thinner 青岛艾尔乐新材料有限公司 2018-09-14 CN claimed
CN-101353827-B Multi-stage phase change micro-nano complex fiber, and preparation method and application thereof CHINESE ACAD INST CHEMISTRY 2010-12-29 CN claimed
CN-101353827-A Multi-stage phase change micro-nano complex fiber, and preparation method and application thereof CHINESE ACAD INST CHEMISTRY (CN) 2009-01-28 CN claimed
US-6440980-B1 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs AVANIR PHARMACEUTICALS 2002-08-27 US claimed
EP-0514009-B1 Corneal treatment agents SUMMIT TECHNOLOGY INC (US) 1995-03-15 EP claimed
CN-117777759-A Modified optically variable dye and preparation method thereof 湖南肆玖科技有限公司 2024-03-29 CN disclosed
EP-3638251-B1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF LAKEWOOD AMEDEX INC (US) 2024-03-06 EP disclosed
CN-117396186-A Anhydrous composition for caring for and/or making up keratin materials 莱雅公司 2024-01-12 CN disclosed
WO-2001072276-A1 NOVEL DELIVERY SYSTEM FOR INORGANIC SUNSCREENS FINETEX, INC. (US) 2001-10-04 WO disclosed
US-5952392-A THERAPEUTIC TREATMENT OF VIRAL INFECTIONS AND SKIN INFLAMMATION USING A MIXTURE CONTAINING A NONIONIC SURFACTANT BLOCK POLYMER AVANIR PHARMACEUTICALS (US) 1999-09-14 US disclosed
US-4150970-A 1-TRIACONTANOL BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 1979-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210361689-A1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF BPGM, PPIP5K2, SOST ALDH1A1 3544/4885TSHR 4193/4885LMNA 3761/4885
US-20200360415-A1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF BPGM, PPIP5K2, SOST ALDH1A1 3544/4885TSHR 4193/4885LMNA 3761/4885
US-20180353529-A1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF BPGM, PPIP5K2, SOST ALDH1A1 3544/4885TSHR 4193/4885LMNA 3761/4885
US-20230125677-A1 BISPHOSPHOCIN GEL FORMULATIONS AND USES THEREOF BPGM, PPIP5K2, SOST ALDH1A1 3544/4885TSHR 4193/4885LMNA 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.